Last close As at 05/08/2026
AUD0.33
▲ 0.01 (1.54%)
Market capitalisation
AUD129m
Research: TMT
EML Payments announced that on 23 April the Financial Conduct Authority (FCA) in the UK lifted the new customer restriction for Prepaid Financial Services Limited (PFSL), which had been in place since October 2022. With the appropriate structure and risk management controls now in place, PFSL can focus on growing the business. This marks another positive step forward for the group, after exiting PFS Card Services Ireland Limited (PFS), agreeing to sell Sentenial and finalising the settlement liabilities for the PFS acquisition.
EML Payments |
Growth cap lifted in the UK |
Regulatory approval |
Software and comp services |
18 March 2024 |
Share price performance
Business description
Analyst
EML Payments is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||
EML Payments announced that on 23 April the Financial Conduct Authority (FCA) in the UK lifted the new customer restriction for Prepaid Financial Services Limited (PFSL), which had been in place since October 2022. With the appropriate structure and risk management controls now in place, PFSL can focus on growing the business. This marks another positive step forward for the group, after exiting PFS Card Services Ireland Limited (PFS), agreeing to sell Sentenial and finalising the settlement liabilities for the PFS acquisition.
Year end |
Revenue |
EBITDA* (A$m) |
PBT** |
Diluted |
DPS |
P/E |
EV/EBITDA* |
06/22 |
232.4 |
51.2 |
16.0 |
3.4 |
0.0 |
31.0 |
8.1 |
06/23 |
254.2 |
37.1 |
(22.8) |
(4.9) |
0.0 |
N/A |
11.2 |
06/24e |
262.1 |
55.7 |
27.5 |
5.7 |
0.0 |
18.4 |
7.5 |
06/25e |
238.0 |
62.5 |
41.4 |
8.6 |
0.0 |
12.3 |
6.7 |
Note: *Underlying. **PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
On 31 October 2022, PFSL (the UK general purpose reloadable business) agreed with the FCA, via a Voluntary Application for Imposition of Requirements (VREQ), to temporarily stop onboarding new customers, agents and distributors. PFSL has since executed a regulatory risk and compliance improvement programme, which was subject to third party assurance review. PFSL successfully applied to the FCA for removal of the VREQ restriction.
With this restriction lifted and the other measures taken by the group noted above, EML is now in a position to focus on profitable growth, with a substantially reduced level of distraction for management.
|
|
Research: Healthcare
Creo Medical has presented real-world evidence of the economic utility of its minimally invasive electrosurgical devices, based on NHS data from 130 submucosal dissection procedures using Creo’s flagship Speedboat Inject device. The data demonstrated net cash savings of £687k for the NHS trust, driven by a significant reduction in both hospitalisation and critical care costs. We believe this provides external validation to Creo’s pursuit of improving patients’ outcomes through its novel suite of devices. Speedboat Inject is currently being assessed by the National Institute for Health and Care Excellence (NICE) and we believe this data could support a positive recommendation and improved NHS adoption.